Form 4: C4 Therapeutics Director Acquires Stock Options

C4 Therapeutics, Inc. reports that Director Owen Hughes acquired 62,000 stock options with an exercise price of $4.25.

Summary

• Owen Hughes, a Director at C4 Therapeutics, Inc., was granted 62,000 stock options on June 24, 2026.
• These options have an exercise price of $4.25 per share.
• The options are set to vest and become exercisable in full on the earlier of June 24, 2027, or the next annual stockholder meeting, provided Hughes remains on the Board.
• The underlying securities are 62,000 shares of Common Stock.
• The transaction was reported on June 26, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it's a standard compensation practice for directors rather than a significant financial event for the company or a strong indicator of immediate stock movement.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The grant of options aligns the director's interests with those of shareholders.
• The exercise price of $4.25 suggests a potential for upside if the stock price increases.

Negatives

• This is a grant of options, not a purchase of stock, meaning no immediate capital is invested by the director.
• The vesting schedule means the director cannot immediately benefit from the options.

Risks

• The value of the options is entirely dependent on the future stock price performance of C4 Therapeutics.
• If the stock price does not exceed $4.25, the options will likely expire worthless.
• The vesting is contingent on continued service, meaning a departure from the board before vesting would forfeit the options.

Future Outlook

The future outlook for the options is tied to the company's stock performance, with full exercisability contingent on continued service and a potential stock price increase above $4.25.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to incentivize leadership and align their financial interests with long-term company growth and shareholder value.

Stakeholder Impact

• Shareholders: The alignment of director incentives with shareholder interests is generally positive, though the actual impact depends on future stock performance.
• Employees: This transaction does not directly impact employees but reflects standard executive compensation practices.
• Management: Reinforces the compensation structure for board members.

Next Steps

• Director Owen Hughes will continue to serve on the Board of Directors.
• The stock options will vest according to the schedule outlined.
• The company's stock price performance will determine the ultimate value of the options.

Key Dates

Keywords

Form 4, Stock Options, C4 Therapeutics, Director, Beneficial Ownership, SEC Filing, Equity Award, Vesting Schedule